AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TELIX PHARMACEUTICALS LTD

26.800

+0.1800.68%

Volume:1.11M

Turnover:29.80M

Market Cap:9.06B

PE:185.34

High:27.170

Open:26.880

Low:26.360

Close:26.620

Loading ...

Overview Company News Filings

Invest $10,000 in these fantastic ASX growth shares

Telix Pharmaceuticals' Potential Brain Cancer Treatment Shows 'Encouraging' Preliminary Results in Study

MT Newswires Live

Telix Reports No Serious Adverse Events Reported in Brain Cancer Combination Therapy Candidate Study

MT Newswires Live

Telix Pharmaceuticals' Prostate Cancer Imaging Agent Illuccix Gets Marketing Authorization in Sweden

MT Newswires Live

5 top ASX 200 stocks that brokers rate as buys after the market selloff

Illuccix® Prostate Cancer Psma-Pet Imaging Agent Approved in Sweden

THOMSON REUTERS

All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy

ASX Midday Sector Update: Financial Stocks Flat, Healthcare Sector Falls

MT Newswires Live

Telix Pharmaceuticals Taps Cardinal Health as Distributor of Prostate Cancer Imaging Agent Gozellix

MT Newswires Live

Telix Selects Cardinal Health for Commercial Distribution of Gozellix in the US

MT Newswires Live

Telix Pharmaceuticals Limited -Selects Cardinal Health as Distributor for Gozellix in U.S.

THOMSON REUTERS

BUZZ-Australia's Telix Pharmaceuticals jumps; UBS says shares undervalued

Telix Looks Materially Undervalued Given Pipeline -- Market Talk

Stock Track | Telix Pharmaceuticals Soars 6.39% as Bell Potter Labels it a Quality Stock at Discount

Bell Potter: 4 quality stocks now at a discount

BRIEF-Telix Appoints Paul Schaffer As Chief Technology Officer

Telix Appoints Paul Schaffer as Chief Technology Officer

THOMSON REUTERS

ASX Market Close: Investors wipe $97B in biggest rout since COVID | April 7, 2025

The Market Herald

Telix Pharmaceuticals Sees No Impact on Business, Supply Chain from US Tariffs, Shares Fall 4%

MT Newswires Live

Telix Pharmaceuticals - Not Impacted by Export Controls Imposed by Chinese Government

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":26.8,"timestamp":1746771120000,"preClose":26.62,"halted":0,"volume":1111086,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":274906865,"shares":337878497,"eps":0.1446,"marketStatus":"Market Closed","change":0.18,"latestTime":"05-09 16:12:00 AEST","open":26.88,"high":27.17,"low":26.36,"amount":29801371,"amplitude":0.030428,"askPrice":26.83,"askSize":8954,"bidPrice":26.76,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":0.1446,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747008000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":26.62,"openAndCloseTimeList":[[1746748800000,1746770400000]],"volumeRatio":0.6589934372030005,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":274906865,"roa":"5.33%","roe":"13.92%","lyrEps":0.150709,"volumeRatio":0.6589934372030005,"shares":337878497,"dividePrice":0,"high":27.17,"amplitude":0.030428,"preClose":26.62,"low":26.36,"week52Low":14.42,"pbRate":"15.94","psRate":"11.56","week52High":31.97,"institutionHeld":0,"latestPrice":26.8,"committee":-0.713029,"eps":0.1446,"divideRate":0,"volume":1111086,"delay":0,"ttmEps":0.1446,"open":26.88,"prevYearClose":24.61,"prevWeekClose":29.32,"prevMonthClose":27.13,"prevQuarterClose":26.52,"fiveDayClose":29.32,"twentyDayClose":24.81,"sixtyDayClose":27.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529357815","title":"Invest $10,000 in these fantastic ASX growth shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2529357815","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529357815?lang=en_us&edition=fundamental","pubTime":"2025-04-22 06:45","pubTimestamp":1745275500,"startTime":"0","endTime":"0","summary":"If you are lucky enough to have $10,000 to invest and also have a penchant for ASX growth shares, then read on!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/22/invest-10000-in-these-fantastic-asx-growth-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7049","NXT.AU","BK7503","BK7107","BK7043","TLX.AU","TPW.AU"],"gpt_icon":0},{"id":"2527825540","title":"Telix Pharmaceuticals' Potential Brain Cancer Treatment Shows 'Encouraging' Preliminary Results in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527825540","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527825540?lang=en_us&edition=fundamental","pubTime":"2025-04-16 15:32","pubTimestamp":1744788751,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Tuesday it received \"encouraging\" preliminary results from an eight-patient phase 2 study of TLX101 in combination with radiation therapy as a potential treatment for recurrent high-grade glioma, a form of brain cancer.The company said the study showed a median overall survival of 12.4 months for patients treated with the TLX101-radiation therapy combo compared with 9.9 months for patients treated with radiation alone.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK4139","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2527402798","title":"Telix Reports No Serious Adverse Events Reported in Brain Cancer Combination Therapy Candidate Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527402798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527402798?lang=en_us&edition=fundamental","pubTime":"2025-04-16 09:55","pubTimestamp":1744768556,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said that its Phase 2 IPAX-Linz study of drug candidate TLX101, in combination with external beam radiation therapy , was well tolerated and showed no serious adverse events in patients with brain cancer, according to a Wednesday filing with the Australian bourse.The study indicated a median overall survival of 12.4 months from treatment initiation, and 32.2 months from diagnosis, the company said.The company has submitted an ethics approval request for a registration-enabling study of TLX101 in recurrent brain cancer, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2527419474","title":"Telix Pharmaceuticals' Prostate Cancer Imaging Agent Illuccix Gets Marketing Authorization in Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419474","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527419474?lang=en_us&edition=fundamental","pubTime":"2025-04-15 23:23","pubTimestamp":1744730601,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Tuesday its prostate cancer imaging agent Illuccix has received marketing authorization from Sweden's Medical Products Agency.This approval came after recent authorizations in Norway and Denmark, the company said.Price: 16.86, Change: +0.03, Percent Change: +0.15","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","TLX","BK7067","BK4139"],"gpt_icon":0},{"id":"2527448763","title":"5 top ASX 200 stocks that brokers rate as buys after the market selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=2527448763","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527448763?lang=en_us&edition=fundamental","pubTime":"2025-04-15 15:10","pubTimestamp":1744701034,"startTime":"0","endTime":"0","summary":"If you are on the lookout for some investment ideas, then it could be worth checking out what analysts saying. Listed below are five ASX 200 stocks that leading brokers currently rate as buy. Here's w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/15/5-top-asx-200-stocks-that-brokers-rate-as-buys-after-the-market-selloff/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7007","RMD.AU","TLX.AU","BK7044","BK7046","BK7016","BK7511","MQG.AU","BK7501","XRO.AU","WTC.AU","JHX.AU","BK7067","BK7503"],"gpt_icon":1},{"id":"2527432489","title":"Illuccix® Prostate Cancer Psma-Pet Imaging Agent Approved in Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2527432489","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527432489?lang=en_us&edition=fundamental","pubTime":"2025-04-15 14:17","pubTimestamp":1744697826,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA7DKSRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2527115590","title":"All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2527115590","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527115590?lang=en_us&edition=fundamental","pubTime":"2025-04-15 00:00","pubTimestamp":1744646410,"startTime":"0","endTime":"0","summary":"Investors might want to bet on Telix Pharmaceuticals Limited , as it has been recently upgraded to a Zacks Rank #2 . This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for Telix Pharmaceuticals Limited is essentially a positive comment on its earnings outlook that could have a favorable impact on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/know-telix-pharmaceuticals-limited-tlx-160010240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TLX.AU","TLX"],"gpt_icon":0},{"id":"2526809186","title":"ASX Midday Sector Update: Financial Stocks Flat, Healthcare Sector Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2526809186","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526809186?lang=en_us&edition=fundamental","pubTime":"2025-04-09 11:34","pubTimestamp":1744169679,"startTime":"0","endTime":"0","summary":"Financial sector stocks were flat on midday Wednesday, with the rest of the sectors on the Australian bourse trading in the red.Regal Partners (ASX:RPL) said that its funds under management came in at","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7062","HCSG","BK7067","RPL.AU","BK4137","TLX.AU"],"gpt_icon":0},{"id":"2526820081","title":"Telix Pharmaceuticals Taps Cardinal Health as Distributor of Prostate Cancer Imaging Agent Gozellix","url":"https://stock-news.laohu8.com/highlight/detail?id=2526820081","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526820081?lang=en_us&edition=fundamental","pubTime":"2025-04-09 08:19","pubTimestamp":1744157967,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) named New York Stock Exchange-listed healthcare company Cardinal Health as one of the commercial radiopharmaceutical distributors of its prostate cancer imaging agent, ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0072461881.USD","LU1267930490.SGD","BK4585","SG9999001440.SGD","TLX","LU1880398554.USD","BK4588","LU1880398471.USD","LU0310800965.SGD","LU0154236417.USD","BK4175","TLX.AU","CAH","LU0310799852.SGD","LU0128525689.USD","LU0006061336.USD","LU0052756011.USD","LU1571399168.USD","LU0211327993.USD","BK7067","LU0792757196.USD","LU1267930813.SGD","LU1267930227.SGD","LU0211328371.USD","LU0162691827.USD","LU0889566641.SGD"],"gpt_icon":0},{"id":"2525984908","title":"Telix Selects Cardinal Health for Commercial Distribution of Gozellix in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2525984908","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525984908?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:08","pubTimestamp":1744110494,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Tuesday that it has selected Cardinal Health (CAH) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix for the treatmen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0072461881.USD","LU1571399168.USD","LU0310800965.SGD","BK4139","LU0128525689.USD","LU1267930227.SGD","TLX","LU0006061336.USD","LU0310799852.SGD","LU1880398554.USD","BK4585","LU1267930490.SGD","BK7067","LU0889566641.SGD","LU0211327993.USD","LU0792757196.USD","LU0154236417.USD","TLX.AU","LU0162691827.USD","LU0052756011.USD","BK4588","CAH","LU1880398471.USD","BK4175","SG9999001440.SGD","LU1267930813.SGD","LU0211328371.USD"],"gpt_icon":0},{"id":"2525201862","title":"Telix Pharmaceuticals Limited -Selects Cardinal Health as Distributor for Gozellix in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525201862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525201862?lang=en_us&edition=fundamental","pubTime":"2025-04-08 18:31","pubTimestamp":1744108307,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM16I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1880398471.USD","LU0052756011.USD","LU0889566641.SGD","LU1571399168.USD","LU0310800965.SGD","LU0211328371.USD","BK7067","LU1267930813.SGD","LU1267930227.SGD","LU0072461881.USD","SG9999001440.SGD","TLX.AU","LU0162691827.USD","LU0310799852.SGD","LU0211327993.USD","LU1880398554.USD","BK4175","LU0006061336.USD","BK4585","LU0128525689.USD","LU0154236417.USD","LU1267930490.SGD","BK4588","CAH","LU0792757196.USD"],"gpt_icon":0},{"id":"2525183324","title":"BUZZ-Australia's Telix Pharmaceuticals jumps; UBS says shares undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2525183324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525183324?lang=en_us&edition=fundamental","pubTime":"2025-04-08 13:00","pubTimestamp":1744088417,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals jumps; UBS says shares undervalued** Telix Pharmaceuticals TLX.AX jumps as much as 7.4% to A$24.87; marks biggest intraday pct gain since February 21** Stock declined for last five straight sessions, hurt by soured investor sentiment amid global trade war** UBS says shares look undervalued, given that co is profitable and manufactures its U.S.-sold products within the country and hence impacted minimally by tariffs** YTD, TLX up 0.7%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nL3N3QM0G6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2525381078","title":"Telix Looks Materially Undervalued Given Pipeline -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2525381078","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525381078?lang=en_us&edition=fundamental","pubTime":"2025-04-08 12:33","pubTimestamp":1744086780,"startTime":"0","endTime":"0","summary":"0433 GMT - Telix Pharmaceuticals' Australia-listed stock looks materially undervalued to UBS analysts given the strength of its therapeutic pipeline. They point out that the stock has been trading below what they calculate to be the combined valuation of Telix's Illuccix, Gozellix, Pixclara and Zircaix products, all of which are either approved for use in the U.S. or stand a good chance of being approved. The scientific and clinical failure that the valuation implies is highly unlikely, they write in a note to clients. With no obvious need to raise external funds and a U.S. manufacturing base, UBS keeps its buy rating and A$36.00 target price on Telix. Shares are up 7.0% at A$24.78. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"1109406862","title":"Stock Track | Telix Pharmaceuticals Soars 6.39% as Bell Potter Labels it a Quality Stock at Discount","url":"https://stock-news.laohu8.com/highlight/detail?id=1109406862","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109406862?lang=en_us&edition=fundamental","pubTime":"2025-04-08 09:50","pubTimestamp":1744077028,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd  saw its stock soaring 6.39% in Tuesday's intraday trading, following a positive assessment from Bell Potter. The broker has identified Telix as one of four quality stocks now trading at a discount, potentially creating an attractive buying opportunity for investors.Bell Potter's analysis highlights Telix's impressive performance, noting a 44% EPS CAGR over the last two years. The company's recent strategic moves, including new product launches and acquisitions, have po","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Telix Pharmaceuticals Soars 6.39% as Bell Potter Labels it a Quality Stock at Discount","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"gpt_icon":0},{"id":"2525938007","title":"Bell Potter: 4 quality stocks now at a discount","url":"https://stock-news.laohu8.com/highlight/detail?id=2525938007","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525938007?lang=en_us&edition=fundamental","pubTime":"2025-04-08 09:16","pubTimestamp":1744075005,"startTime":"0","endTime":"0","summary":"The one silver lining to widespread market sell-offs is that quality companies can get caught in the crossfire.With uncertainty the order of the day, the quest for quality takes centre stage.Bell Potter has released its pick of the best stock picks that it believes are now undervalued following the recent market turmoil.Sentiment-driven selloffs can impact all stocks, meaning even high-quality, fundamentally sound businesses can experience valuation compression unrelated to their intrinsic worth. This creates valuable windows to buy quality stocks at more reasonable valuations.While valuations have dropped, aggregate market earnings forecasts over the last 6 weeks remain strong, opening the door to buying opportunities.Bell Potter’s “quality at a discount” screen searched for companies based on balance sheet strength, high and sustainable returns on equity and consistent profitability.It then assesses their potential for growth, earnings momentum and looks for stocks with notable P/E c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/bell-potter-4-quality-stocks-now-at-a-discount","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/bell-potter-4-quality-stocks-now-at-a-discount","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7078","BK7002","BK7007","BK4091","RMD.AU","GGR","ALL.AU","REA.AU","BK7501","GGR.AU","TLX.AU","BK7067","BK7503"],"gpt_icon":0},{"id":"2525015109","title":"BRIEF-Telix Appoints Paul Schaffer As Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2525015109","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525015109?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:31","pubTimestamp":1744021893,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Appoints Paul Schaffer As Chief Technology OfficerApril 7 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:TELIX APPOINTS PAUL SCHAFFER AS CHIEF TECHNOLOGY OFFICERSource text: ID:nGNX7c7KTsFurther company coverage: TLX.AX (((( Reuters.briefs@thomsonreuters.com ;));))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nTUAC2GKG4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2525151320","title":"Telix Appoints Paul Schaffer as Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2525151320","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525151320?lang=en_us&edition=fundamental","pubTime":"2025-04-07 18:30","pubTimestamp":1744021800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nTUAC2GKG4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2525062724","title":"ASX Market Close: Investors wipe $97B in biggest rout since COVID | April 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525062724","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525062724?lang=en_us&edition=fundamental","pubTime":"2025-04-07 14:59","pubTimestamp":1744009140,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 4.2% at 7,343 points in a $97B wipeout for the market.The Energy sector was decimated, down 7%, followed by Financials, down 5%, and Materials and Discretionary – both down 4.8%.Lynas Rare News  closed up 3.1% after Aussie-listed miners of heavy rare earths rallied today, shrugging off major selloffs across other markets on bets Western governments would renew their push to develop a separate supply chain after top producer China set down export controls.Nyrada closed up 4.8% on reports of neuroprotective results for its lead drug candidate in a collaborative traumatic brain injury study with the Walter Reed Army Institute of Research and UNSW Sydney.Abacus Storage King  closed up 20.7% on news of an unsolicited takeover offer from a consortium, valuing the firm at around A$1.9 billion.Kelsian Groupfinished down 8.3% today despite developments in itsU.S.operations, where its wholly owned subsidiary, First Class Transportation, secured contract renewals and new bu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-investors-wipe-97b-in-biggest-rout-since-covid-april-7-2025-2025-04-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7161","WDS.AU","BK7507","BK7125","BK7142","ISBC","BK7067","LYC.AU","TLX.AU","BK7096","ASK.AU","BK7151","BK4211","KLS.AU","NYR.AU","BK7095"],"gpt_icon":0},{"id":"2525052643","title":"Telix Pharmaceuticals Sees No Impact on Business, Supply Chain from US Tariffs, Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2525052643","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525052643?lang=en_us&edition=fundamental","pubTime":"2025-04-07 12:37","pubTimestamp":1744000631,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  does not expect any material impact on its business or supply chain from the international trade tariffs announced by the US government on April 2, according to a Monday Australian bourse filing.It noted that it had an extensive US-based manufacturing and distribution infrastructure with third-party manufacturing sites and radiopharmacy partner networks. Pharmaceutical products are currently exempt from the tariffs.The firm also said that the Food and Drug Administration continues to process applications and information requests, despite reports of changes at the agency, and that the firm has not been notified of any changes to the timelines for its new drug application for Pixclara or biologics license application for Zircaix.Its shares fell 4% in recent trading on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2525768056","title":"Telix Pharmaceuticals - Not Impacted by Export Controls Imposed by Chinese Government","url":"https://stock-news.laohu8.com/highlight/detail?id=2525768056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525768056?lang=en_us&edition=fundamental","pubTime":"2025-04-07 11:37","pubTimestamp":1743997071,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL008:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null},{"date":"2023-08-23","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692748800000,"name":null,"time":"","dateTimestamp":1692712800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[]}}